2010
Future directions in multimodality therapy for NSCLC
Tsao AS, Roth JA, Herbst RS. Future directions in multimodality therapy for NSCLC. Nature Reviews Clinical Oncology 2010, 7: 10-12. PMID: 20029443, DOI: 10.1038/nrclinonc.2009.174.Peer-Reviewed Original Research
2009
Phase II pilot study of neoadjuvant docetaxel and cisplatin followed by adjuvant erlotinib in patients with stage I-III non-small cell lung cancer (NSCLC)
Gold K, Lee J, Rice D, Tse W, Stewart D, Wistuba I, Herbst R, Lippman S, Hong W, Kim E. Phase II pilot study of neoadjuvant docetaxel and cisplatin followed by adjuvant erlotinib in patients with stage I-III non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2009, 27: 7566-7566. DOI: 10.1200/jco.2009.27.15_suppl.7566.Peer-Reviewed Original ResearchNon-small cell lung cancerStage ISurgical resectionResectable non-small cell lung cancerEarly-stage non-small cell lung cancerStage non-small cell lung cancerResponse rateECOG performance status 0Phase II pilot studyAdequate laboratory parametersCurative-intent therapyCycles of chemotherapyDefinitive surgical resectionGrade 3/4 toxicitiesPerformance status 0Radiographic response rateBenefit of chemotherapyComplete pathologic responseEncouraging response ratesCell lung cancerYr of treatmentActive regimenAdjuvant erlotinibCancer ptsEligible pts